Biotechnology

Biogen

$265.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$6.52 (-2.40%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Biogen and other stocks, options, and ETFs commission-free!

About BIIB

Biogen Inc. Common Stock, also called Biogen, is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. The listed name for BIIB is Biogen Inc. Common Stock.

CEO
Michel Vounatsos
Employees
7,400
Headquarters
Cambridge, Massachusetts
Founded
1978
Market Cap
40.00B
Price-Earnings Ratio
9.12
Dividend Yield
—
Average Volume
1.39M
High Today
$268.66
Low Today
$262.99
Open Price
$267.70
Volume
1.11M
52 Week High
$374.99
52 Week Low
$223.25

Collections

BIIB Earnings

$0.00
$3.42
$6.84
$10.26
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Feb 3, Pre-Market

You May Also Like

UAMY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure